200 related articles for article (PubMed ID: 18356837)
21. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
[TBL] [Abstract][Full Text] [Related]
22. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
[TBL] [Abstract][Full Text] [Related]
23. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
[TBL] [Abstract][Full Text] [Related]
24. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
[TBL] [Abstract][Full Text] [Related]
25. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
Hansen D; Astrup A; Toubro S; Finer N; Kopelman P; Hilsted J; Rössner S; Saris W; Van Gaal L; James W; Goulder M;
Int J Obes Relat Metab Disord; 2001 Apr; 25(4):496-501. PubMed ID: 11319653
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity.
Gatta-Cherifi B; Matias I; Vallée M; Tabarin A; Marsicano G; Piazza PV; Cota D
Int J Obes (Lond); 2012 Jun; 36(6):880-5. PubMed ID: 21844878
[TBL] [Abstract][Full Text] [Related]
27. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
[TBL] [Abstract][Full Text] [Related]
28. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity.
Blüher M; Engeli S; Klöting N; Berndt J; Fasshauer M; Bátkai S; Pacher P; Schön MR; Jordan J; Stumvoll M
Diabetes; 2006 Nov; 55(11):3053-60. PubMed ID: 17065342
[TBL] [Abstract][Full Text] [Related]
29. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
30. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
[TBL] [Abstract][Full Text] [Related]
31. Effects of sibutramine on resting metabolic rate and weight loss in overweight women.
Seagle HM; Bessesen DH; Hill JO
Obes Res; 1998 Mar; 6(2):115-21. PubMed ID: 9545017
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.
Henderson DC; Fan X; Copeland PM; Borba CP; Daley TB; Nguyen DD; Zhang H; Hayden D; Freudenreich O; Cather C; Evins AE; Goff DC
Acta Psychiatr Scand; 2007 Feb; 115(2):101-5. PubMed ID: 17244173
[TBL] [Abstract][Full Text] [Related]
33. Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure.
Weis F; Beiras-Fernandez A; Sodian R; Kaczmarek I; Reichart B; Beiras A; Schelling G; Kreth S
J Mol Cell Cardiol; 2010 Jun; 48(6):1187-93. PubMed ID: 19931541
[TBL] [Abstract][Full Text] [Related]
34. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
[TBL] [Abstract][Full Text] [Related]
35. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
[TBL] [Abstract][Full Text] [Related]
36. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
[TBL] [Abstract][Full Text] [Related]
37. [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
Tong NW; Ran XW; Li QF; Tang BD; Li R; Yang FY; Liu YP; Li XJ
Zhonghua Nei Ke Za Zhi; 2005 Sep; 44(9):659-63. PubMed ID: 16202254
[TBL] [Abstract][Full Text] [Related]
38. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet.
Starowicz KM; Cristino L; Matias I; Capasso R; Racioppi A; Izzo AA; Di Marzo V
Obesity (Silver Spring); 2008 Mar; 16(3):553-65. PubMed ID: 18239598
[TBL] [Abstract][Full Text] [Related]
39. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
[TBL] [Abstract][Full Text] [Related]
40. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
